Y Intercept Hong Kong Ltd Increases Stake in Compass Therapeutics, Inc. $CMPX

Y Intercept Hong Kong Ltd boosted its position in Compass Therapeutics, Inc. (NASDAQ:CMPX) by 79.3% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 828,879 shares of the company’s stock after acquiring an additional 366,713 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Compass Therapeutics were worth $4,385,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Suvretta Capital Management LLC increased its stake in shares of Compass Therapeutics by 97.2% in the third quarter. Suvretta Capital Management LLC now owns 14,101,159 shares of the company’s stock worth $49,354,000 after purchasing an additional 6,951,666 shares in the last quarter. Vivo Capital LLC lifted its stake in shares of Compass Therapeutics by 57.9% during the 3rd quarter. Vivo Capital LLC now owns 9,545,466 shares of the company’s stock valued at $33,409,000 after buying an additional 3,502,000 shares in the last quarter. BVF Inc. IL boosted its holdings in Compass Therapeutics by 63.5% in the 4th quarter. BVF Inc. IL now owns 7,764,842 shares of the company’s stock worth $41,697,000 after buying an additional 3,014,842 shares during the period. Balyasny Asset Management L.P. bought a new position in Compass Therapeutics in the 3rd quarter worth approximately $9,892,000. Finally, Braidwell LP purchased a new position in Compass Therapeutics in the 4th quarter valued at approximately $14,965,000. 68.43% of the stock is owned by hedge funds and other institutional investors.

Compass Therapeutics Price Performance

NASDAQ CMPX opened at $2.27 on Monday. Compass Therapeutics, Inc. has a 1 year low of $1.61 and a 1 year high of $6.88. The stock has a market capitalization of $408.80 million, a PE ratio of -5.54 and a beta of 0.90. The company’s 50 day simple moving average is $2.14 and its two-hundred day simple moving average is $4.41.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.10) EPS for the quarter, meeting the consensus estimate of ($0.10). On average, research analysts anticipate that Compass Therapeutics, Inc. will post -0.42 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on CMPX shares. Canaccord Genuity Group dropped their target price on Compass Therapeutics from $13.00 to $7.00 and set a “buy” rating on the stock in a research report on Tuesday, April 28th. LADENBURG THALM/SH SH started coverage on Compass Therapeutics in a research report on Wednesday, July 1st. They issued a “buy” rating and a $5.00 price target for the company. Raymond James Financial cut Compass Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, April 28th. Wall Street Zen downgraded Compass Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $24.00 target price on shares of Compass Therapeutics in a report on Monday, April 27th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $12.25.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.